Synthesis and biocompatibility of an argatroban-modified polysulfone membrane that directly inhibits thrombosis

Fu, Xiao; Ning, Jianping

doi:10.1007/s10856-018-6054-4

Cited by 29 publications

(18 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A modified polysulfone membrane with a direct thrombin inhibitor, Argatroban, was chemically grafted to enhance the hydrophilicity and induced protein adsorption, coagulation, and platelet and complement activation [51].…”

Section: Complementmentioning

confidence: 99%

Immune System Dysfunction and Inflammation in Hemodialysis Patients: Two Sides of the Same Coin

Campo

Lacquaniti

Trombetta

et al. 2022

JCM

View full text Add to dashboard Cite

Biocompatibility in hemodialysis (HD) has considerably improved in recent decades, but remains an open issue to be solved, appearing essential to reduce systemic inflammation and enhance patients’ clinical outcomes. Clotting prevention, reduction in complement and leukocyte activation, and improvement of antioxidant effect represent the main goals. This review aims to analyze the different pathways involved in HD patients, leading to immune system dysfunction and inflammation. In particular, we mostly review the evidence about thrombogenicity, which probably represents the most important characteristic of bio-incompatibility. Platelet activation is one of the first steps occurring in HD patients, determining several events causing chronic sub-clinical inflammation and immune dysfunction involvement. Moreover, oxidative stress processes, resulting from a loss of balance between pro-oxidant factors and antioxidant mechanisms, have been described, highlighting the link with inflammation. We updated both innate and acquired immune system dysfunctions and their close link with uremic toxins occurring in HD patients, with several consequences leading to increased mortality. The elucidation of the role of immune dysfunction and inflammation in HD patients would enhance not only the understanding of disease physiopathology, but also has the potential to provide new insights into the development of therapeutic strategies.

show abstract

Section: Complementmentioning

confidence: 99%

Immune System Dysfunction and Inflammation in Hemodialysis Patients: Two Sides of the Same Coin

Campo

Lacquaniti

Trombetta

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Protein adsorption, which plays a critical role in blood coagulation, is considered the first step in contact activation. Analysis of protein adsorption was performed using solutions of BSA and BFG under static condition . Firstly, dried membranes with a surface area of 1 × 1 cm were pretreated with phosphate buffered saline (PBS, pH = 7.4) at 4°C for 24 hours.…”

Section: Methodsmentioning

confidence: 99%

“…Analysis of protein adsorption was performed using solutions of BSA and BFG under static condition. [32][33][34] Firstly, dried membranes with a surface area of…”

Section: Protein Adsorptionmentioning

confidence: 99%

Improvement in the blood compatibility of polyvinylidene fluoride membranes via in situ cross‐linking polymerization

Nie

Zeng

Qin

et al. 2018

Polymers for Advanced Techs

View full text Add to dashboard Cite

In this study, we have provided a highly efficient, convenient, and universal protocol for preparing polyvinylidene fluoride (PVDF) membranes with low blood contact activation via in situ cross‐linking copolymerization of 2‐hydroxyethl methacrylate (HEMA) and acrylic acid (AA) in a solution of PVDF. The modified membranes were prepared from PVDF solution by phase inversion technology. The composition and morphology of the modified membranes were confirmed by attenuated total reflectance‐Fourier transform infrared (ATR‐FTIR) spectroscopy, thermogravimetric (TG) analysis, and scanning electron microscopy (SEM). Protein adsorption, clotting time, and contact activation on the modified PVDF membranes were systematically studied, the results indicating that after the incorporation of AA and HEMA, the modified PVDF membranes possessed anticoagulant properties in addition to low contact activation of blood components when in contact with blood. Therefore, fluorinated PVDF membranes with surfaces enriched with carboxyl and hydroxyl groups possessed the potential for use in long‐term blood‐contacting devices.

show abstract

“…70 Therefore, increasing the surface hydrophilicity of the polymer was also an effective way to greatly reduce protein adsorption, coagulation, as well as activation of platelets and the complement system. 71 3.5. Cellular Uptake Assay.…”

Section: 3mentioning

confidence: 99%

Vinblastine-Loaded Nanoparticles with Enhanced Tumor-Targeting Efficiency and Decreasing Toxicity: Developed by One-Step Molecular Imprinting Process

et al. 2019

View full text Add to dashboard Cite

Molecularly imprinted polymers have exhibited good performance as carriers on drug loading and sustained release. In this paper, vinblastine (VBL)-loaded polymeric nanoparticles (VBL–NPs) were prepared by a one-step molecular imprinting process, avoiding the waste and incomplete removal of the template, and evaluated as targeting carriers for VBL delivery after modification. Using acryloyl amino acid comonomers and disulfide cross-linkers, VBL–NPs were synthesized and then conjugated with poly(ethylene glycol)–folate. The dynamic size of the obtained VBL–NPs–PEG–FA was 258.3 nm (PDI = 0.250), and the encapsulation efficiency was 45.82 ± 1.45%. The nanoparticles of VBL–NPs–PEG–FA were able to completely release VBL during 48 h under a mimic tumor intracellular condition (pH 4.5, 10 mM glutathione (GSH)), displaying significant redox responsiveness, whereas the release rates were much slower in the mimic body liquid (pH 7.4, 2 μM GSH) and tumor extracellular environment (pH 6.5, 2 μM GSH). Furthermore, the carriers NPs–PEG–FA, prepared without VBL, showed satisfactory intrinsic hemocompatibility, cellular compatibility, and tumor-targeting properties: they could rapidly and efficiently accumulate to folate receptor positive Hela cells and then internalized via receptor-mediated endocytosis, and the retention in tumor tissues could last for over 48 h. Interestingly, VBL–NPs–PEG–FA could evidently increase the accumulation of VBL in tumor tissues while decreasing the distribution of VBL in organs, exert similar anticancer efficacy against Hela tumors in the xenograft model of nude mice to VBL injection, and significantly improve the abnormality of liver and spleen observed in VBL injection. VBL–NPs–PEG–FA has the potential to be the delivery carrier for VBL by enhancing the tumor-targeting efficacy of VBL and decreasing toxicity to normal tissues.

show abstract

Synthesis and biocompatibility of an argatroban-modified polysulfone membrane that directly inhibits thrombosis

Cited by 29 publications

References 60 publications

Immune System Dysfunction and Inflammation in Hemodialysis Patients: Two Sides of the Same Coin

Immune System Dysfunction and Inflammation in Hemodialysis Patients: Two Sides of the Same Coin

Improvement in the blood compatibility of polyvinylidene fluoride membranes via in situ cross‐linking polymerization

Vinblastine-Loaded Nanoparticles with Enhanced Tumor-Targeting Efficiency and Decreasing Toxicity: Developed by One-Step Molecular Imprinting Process

Contact Info

Product

Resources

About